



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 074 617 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
07.02.2001 Bulletin 2001/06

(51) Int Cl.⁷: **C12N 15/12, C12N 15/11,
C07K 14/47, C07K 16/18,
C12Q 1/68**

(21) Application number: **00116126.4**

(22) Date of filing: **28.07.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **29.07.1999 JP 24803699
27.08.1999 JP 30025399
11.01.2000 JP 2000118776
02.05.2000 JP 2000183767
09.06.2000 JP 2000241899**

(71) Applicant: **Helix Research Institute
Kisarazu-shi, Chiba 292-0812 JP**

(72) Inventors:
• **Ota, Toshio**
Fujisawa-shi, Kanagawa 251-0042 JP
• **Isogai, Takao**
Inashiki-gun, Ibaraki 300-0303 JP
• **Nishikawa, Tetsuo**
Itabashi-ku, Tokyo 173-0013 JP

- **Hayashi, Kohji**
Ichihara-shi, Chiba 292-0056 JP
- **Saito, Kaoru**
Kisarazu-shi, Chiba 292-0056 JP
- **Yamamoto, Junichi**
Kisarazu-shi, Chiba 292-0041 JP
- **Ishii, Shizuko**
Kisarazu-shi, Chiba 292-0812 JP
- **Sugiyama, Tomoyasu**
Kisarazu-shi, Chiba 292-0045 JP
- **Wakamatsu, Ai**
Kisarazu-shi, Chiba 292-0014 JP
- **Nagai, Keiichi**
Higashiyamato-shi, Tokyo 207-0022 JP
- **Otsuki, Tetsuji**
Kisarazu-shi, Chiba 292-0045 JP

(74) Representative: **VOSSIUS & PARTNER
Siebertstrasse 4
81675 München DE**

(54) **Primers for synthesising full-length cDNA and their use**

(57) Primers for synthesizing full-length cDNAs and their use are provided.

5602 cDNA encoding a human protein has been isolated and nucleotide sequences of 5'-, and 3'-ends of the cDNA have been determined. Furthermore, prim-

ers for synthesizing the full-length cDNA have been provided to clarify the function of the protein encoded by the cDNA. The full-length cDNA of the present invention containing the translation start site provides information useful for analyzing the functions of the protein.

EP 1 074 617 A2

forth in any one of SEQ ID NOs: 1-5547 and SEQ ID NOs: 16111-16164, or the complementary strand thereof, wherein said oligonucleotide is complementary to said polynucleotide or the complementary strand thereof and comprises at least 15 nucleotides.

- 5 2. A primer set for synthesizing polynucleotides, the primer set comprising an oligo-dT primer and an oligonucleotide complementary to the complementary strand of the polynucleotide comprising the nucleotide sequence set forth in any one of SEQ ID NOs: 1-5547 and SEQ ID NOs: 16111-16164, wherein said oligonucleotide comprises at least 15 nucleotides.
- 10 3. A primer set for synthesizing polynucleotides, the primer set comprising a combination of an oligonucleotide comprising a nucleotide sequence complementary to the complementary strand of the polynucleotide comprising a 5'-end nucleotide sequence and an oligonucleotide comprising a nucleotide sequence complementary to the polynucleotide comprising a 3'-end nucleotide sequence, wherein said oligonucleotides comprise at least 15 nucleotides and wherein said combination of 5'-end nucleotide sequence 3'-end nucleotide sequence is selected from
- 15 the group consisting of:

SEQ ID NO: 1 / SEQ ID NO: 5548, SEQ ID NO: 4 / SEQ ID NO: 5549, SEQ ID NO: 5 / SEQ ID NO: 5550, SEQ ID NO: 6 / SEQ ID NO: 5551, SEQ ID NO: 7 / SEQ ID NO: 5552, SEQ ID NO: 8 / SEQ ID NO: 5553, SEQ ID NO: 9 / SEQ ID NO: 5554, SEQ ID NO: 10 / SEQ ID NO: 5555, SEQ ID NO: 11 / SEQ ID NO: 5556, SEQ ID NO: 12 / SEQ ID NO: 5557, SEQ ID NO: 13 / SEQ ID NO: 5558, SEQ ID NO: 14 / SEQ ID NO: 5559, SEQ ID NO: 15 / SEQ ID NO: 5560, SEQ ID NO: 16 / SEQ ID NO: 5561, SEQ ID NO: 17 / SEQ ID NO: 5562, SEQ ID NO: 18 / SEQ ID NO: 5563, SEQ ID NO: 19 / SEQ ID NO: 5564, SEQ ID NO: 20 / SEQ ID NO: 5565, SEQ ID NO: 21 / SEQ ID NO: 5566, SEQ ID NO: 22 / SEQ ID NO: 5567, SEQ ID NO: 23 / SEQ ID NO: 5568, SEQ ID NO: 24 / SEQ ID NO: 5569, SEQ ID NO: 25 / SEQ ID NO: 5570, SEQ ID NO: 26 / SEQ ID NO: 5571, SEQ ID NO: 27 / SEQ ID NO: 5572, SEQ ID NO: 28 / SEQ ID NO: 5573, SEQ ID NO: 29 / SEQ ID NO: 5574, SEQ ID NO: 30 / SEQ ID NO: 5575, SEQ ID NO: 31 / SEQ ID NO: 5576, SEQ ID NO: 32 / SEQ ID NO: 5577, SEQ ID NO: 33 / SEQ ID NO: 5578, SEQ ID NO: 34 / SEQ ID NO: 5579, SEQ ID NO: 35 / SEQ ID NO: 5580, SEQ ID NO: 37 / SEQ ID NO: 5581, SEQ ID NO: 38 / SEQ ID NO: 5582, SEQ ID NO: 39 / SEQ ID NO: 5583, SEQ ID NO: 40 / SEQ ID NO: 5584, SEQ ID NO: 42 / SEQ ID NO: 5585, SEQ ID NO: 43 / SEQ ID NO: 5586, SEQ ID NO: 44 / SEQ ID NO: 5587, SEQ ID NO: 45 / SEQ ID NO: 5588, SEQ ID NO: 46 / SEQ ID NO: 5589, SEQ ID NO: 47 / SEQ ID NO: 5590, SEQ ID NO: 48 / SEQ ID NO: 5591, SEQ ID NO: 49 / SEQ ID NO: 5592, SEQ ID NO: 50 / SEQ ID NO: 5593, SEQ ID NO: 51 / SEQ ID NO: 5594, SEQ ID NO: 52 / SEQ ID NO: 5595, SEQ ID NO: 53 / SEQ ID NO: 5596, SEQ ID NO: 54 / SEQ ID NO: 5597, SEQ ID NO: 55 / SEQ ID NO: 5598, SEQ ID NO: 56 / SEQ ID NO: 5599, SEQ ID NO: 57 / SEQ ID NO: 5600, SEQ ID NO: 58 / SEQ ID NO: 5601, SEQ ID NO: 59 / SEQ ID NO: 5602, SEQ ID NO: 60 / SEQ ID NO: 5603, SEQ ID NO: 61 / SEQ ID NO: 5604, SEQ ID NO: 62 / SEQ ID NO: 5605, SEQ ID NO: 63 / SEQ ID NO: 5606, SEQ ID NO: 65 / SEQ ID NO: 5607, SEQ ID NO: 66 / SEQ ID NO: 5608, SEQ ID NO: 67 / SEQ ID NO: 5609, SEQ ID NO: 68 / SEQ ID NO: 5610, SEQ ID NO: 69 / SEQ ID NO: 5611, SEQ ID NO: 70 / SEQ ID NO: 5612, SEQ ID NO: 71 / SEQ ID NO: 5613, SEQ ID NO: 72 / SEQ ID NO: 5614, SEQ ID NO: 74 / SEQ ID NO: 5615, SEQ ID NO: 76 / SEQ ID NO: 5616, SEQ ID NO: 77 / SEQ ID NO: 5617, SEQ ID NO: 78 / SEQ ID NO: 5618, SEQ ID NO: 79 / SEQ ID NO: 5619, SEQ ID NO: 80 / SEQ ID NO: 5620, SEQ ID NO: 81 / SEQ ID NO: 5621, SEQ ID NO: 82 / SEQ ID NO: 5622, SEQ ID NO: 83 / SEQ ID NO: 5623, SEQ ID NO: 84 / SEQ ID NO: 5624, SEQ ID NO: 85 / SEQ ID NO: 5625, SEQ ID NO: 86 / SEQ ID NO: 5626, SEQ ID NO: 87 / SEQ ID NO: 5627, SEQ ID NO: 88 / SEQ ID NO: 5628, SEQ ID NO: 89 / SEQ ID NO: 5629, SEQ ID NO: 90 / SEQ ID NO: 5630, SEQ ID NO: 91 / SEQ ID NO: 5631, SEQ ID NO: 92 / SEQ ID NO: 5632, SEQ ID NO:

NO: 16216, SEQ ID NO: 16163 / SEQ ID NO: 16217, and SEQ ID NO: 16164 / SEQ ID NO: 16218

- 5 4. A polynucleotide which can be synthesized with the primer set of claim 2 or 3.
5. A polynucleotide comprising a coding region in the polynucleotide of claim 4.
6. A substantially pure protein encoded by polynucleotide of claim 4.
- 10 7. A partial peptide of the protein of claim 6.
8. An isolated polynucleotide selected from the group consisting of
- 15 (a) a polynucleotide comprising a coding region of the nucleotide sequence set forth in any one of the following
 SEQ ID NOs:
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55